LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Article ; Online: Should intralesional bleomycin be used in the treatment of human papillomavirus-related genital disease in the immunocompromised host?

    Krulig, Eliana / Worobec, Sophie Marie

    Journal of the American Academy of Dermatology

    2013  Volume 68, Issue 4, Page(s) 680–681

    MeSH term(s) Alphapapillomavirus ; Female ; Humans ; Immunocompromised Host ; Male ; Papillomavirus Infections/therapy ; Penile Neoplasms/therapy ; Vaginal Neoplasms/therapy ; Vulvar Neoplasms/therapy ; Warts/therapy
    Language English
    Publishing date 2013-04
    Publishing country United States
    Document type Comment ; Letter
    ZDB-ID 603641-7
    ISSN 1097-6787 ; 0190-9622
    ISSN (online) 1097-6787
    ISSN 0190-9622
    DOI 10.1016/j.jaad.2012.08.047
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1540: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Periorbital indurated lesions in a 67-year-old female patient.

    Kazlouskaya, Viktoryia / Blochin, Elen / Krulig, Eliana / Fong, Danny / Elston, Dirk

    International journal of dermatology

    2015  Volume 54, Issue 2, Page(s) 143–145

    MeSH term(s) Aged ; Eyelid Diseases/pathology ; Facial Dermatoses/pathology ; Female ; Granuloma/pathology ; Humans ; Xanthomatosis/pathology
    Language English
    Publishing date 2015-02
    Publishing country England
    Document type Case Reports ; Journal Article
    ZDB-ID 412254-9
    ISSN 1365-4632 ; 0011-9059 ; 1461-1244
    ISSN (online) 1365-4632
    ISSN 0011-9059 ; 1461-1244
    DOI 10.1111/ijd.12580
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui VI Zs.189: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis.

    Krulig, Eliana / Gordon, Kenneth B

    Core evidence

    2010  Volume 5, Page(s) 11–22

    Abstract: Introduction: Psoriasis is a chronic inflammatory skin disease affecting approximately 2% to 3% of the population worldwide. Discoveries over the past 3 to 5 years have significantly altered our view of psoriasis as primarily a T-cell mediated condition. ...

    Abstract Introduction: Psoriasis is a chronic inflammatory skin disease affecting approximately 2% to 3% of the population worldwide. Discoveries over the past 3 to 5 years have significantly altered our view of psoriasis as primarily a T-cell mediated condition. The most recent research has demonstrated the essential role of specific cytokines in the development of this complex disease, including TNF-alpha, interleukin-23 (IL-23), and potentially, IL-22. These are all part of a newly defined autoimmune pathway directed by specialized T cells called Th17 helper T cells. Ustekinumab is a fully human monoclonal antibody that targets IL-12 and IL-23, thus targeting both Th1 and Th17 arms of immunity. It has a promising efficacy and safety profile that not only represents a valuable treatment alternative, but also a continuation in our constantly evolving understanding of this disorder.
    Aims: To review the emerging evidence supporting the use of ustekinumab in the management of moderate to severe plaque psoriasis.
    Evidence review: There is clear evidence that ustekinumab is effective in the treatment of moderate to severe psoriasis. Phase III trials (PHOENIX 1 and 2) demonstrated a statistically significant difference between Psoriasis Area and Severity Index (PASI) 75 responses achieved by patients receiving ustekinumab, given as a 45 mg or 90 mg subcutaneous injection every 12 weeks, than their placebo counterparts. Treatment with this novel agent resulted in a rapid onset of action, with over 60% of treated patients attaining Physician's Global Assessment (PGA) scores of "cleared" or "minimal" by week 12. Quality of life assessments paralleled clinical improvements.
    Clinical potential: Ustekinumab is an effective and efficient therapeutic option for patients with moderate to severe psoriasis. Although further studies are required to establish ustekinumab's place in the therapy of psoriasis, with its convenient dosing schedule and rapid onset of action, this drug could provide a great addition to the current therapeutic armamentarium available for psoriatic patients.
    Language English
    Publishing date 2010-07-27
    Publishing country New Zealand
    Document type Journal Article
    ZDB-ID 2520695-3
    ISSN 1555-175X ; 1555-175X
    ISSN (online) 1555-175X
    ISSN 1555-175X
    DOI 10.2147/ce.s5994
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Acquired microcystic lymphatic malformation of the distal upper extremity mimicking verrucae vulgaris.

    Wang, Stephanie / Krulig, Eliana / Hernandez, Claudia

    Pediatric dermatology

    2013  Volume 30, Issue 5, Page(s) e78–82

    Abstract: An 18-year-old African American male with a history of congenital lymphedema of the right upper extremity presented for evaluation of multiple verrucous lesions on his right hand. Clusters of 2 to 4-mm dome-shaped vesicles were intermixed with scattered ... ...

    Abstract An 18-year-old African American male with a history of congenital lymphedema of the right upper extremity presented for evaluation of multiple verrucous lesions on his right hand. Clusters of 2 to 4-mm dome-shaped vesicles were intermixed with scattered verrucous papules on the right forearm and the dorsal and palmar aspects of the hand. Histopathology of one the verrucous lesions showed well-circumscribed areas of dilated lymphatic vascular channels with lymph in the lumen. The patient was diagnosed with microcystic lymphatic malformation, verrucous type. This article reviews the literature regarding reports of this variant of microcystic lymphatic malformation in the pediatric population.
    MeSH term(s) Adolescent ; Arm/pathology ; Biopsy ; Blister/diagnosis ; Blister/pathology ; Diagnosis, Differential ; Humans ; Lymphatic Vessels/abnormalities ; Lymphedema/congenital ; Lymphedema/diagnosis ; Lymphedema/pathology ; Male ; Warts/diagnosis
    Language English
    Publishing date 2013-09
    Publishing country United States
    Document type Case Reports ; Journal Article ; Review
    ZDB-ID 605539-4
    ISSN 1525-1470 ; 0736-8046
    ISSN (online) 1525-1470
    ISSN 0736-8046
    DOI 10.1111/pde.12179
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1882: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Ustekinumab

    Eliana Krulig / Kenneth B Gordon

    Core Evidence, Vol 2010, Iss default, Pp 11-

    an evidence-based review of its effectiveness in the treatment of psoriasis

    2010  Volume 22

    Abstract: Eliana Krulig, Kenneth B GordonNorthShore University HealthSystem, University of Chicago, Pritzker ...

    Abstract Eliana Krulig, Kenneth B GordonNorthShore University HealthSystem, University of Chicago, Pritzker School of Medicine, Skokie, IL, USAIntroduction: Psoriasis is a chronic inflammatory skin disease affecting approximately 2% to 3% of the population worldwide. Discoveries over the past 3 to 5 years have significantly altered our view of psoriasis as primarily a T-cell mediated condition. The most recent research has demonstrated the essential role of specific cytokines in the development of this complex disease, including TNF-, interleukin-23 (IL-23), and potentially, IL-22. These are all part of a newly defined autoimmune pathway directed by specialized T cells called Th17 helper T cells. Ustekinumab is a fully human monoclonal antibody that targets IL-12 and IL-23, thus targeting both Th1 and Th17 arms of immunity. It has a promising efficacy and safety profile that not only represents a valuable treatment alternative, but also a continuation in our constantly evolving understanding of this disorder.Aims: To review the emerging evidence supporting the use of ustekinumab in the management of moderate to severe plaque psoriasis.Evidence review: There is clear evidence that ustekinumab is effective in the treatment of moderate to severe psoriasis. Phase III trials (PHOENIX 1 and 2) demonstrated a statistically significant difference between Psoriasis Area and Severity Index (PASI) 75 responses achieved by patients receiving ustekinumab, given as a 45 mg or 90 mg subcutaneous injection every 12 weeks, than their placebo counterparts. Treatment with this novel agent resulted in a rapid onset of action, with over 60% of treated patients attaining Physician’s Global Assessment (PGA) scores of “cleared” or “minimal” by week 12. Quality of life assessments paralleled clinical improvements.Clinical potential: Ustekinumab is an effective and efficient therapeutic option for patients with moderate to severe psoriasis. Although further studies are required to establish ustekinumab’s place in the therapy of psoriasis, with its convenient dosing schedule and rapid onset of action, this drug could provide a great addition to the current therapeutic armamentarium available for psoriatic patients. Keywords: ustekinumab, psoriasis, biologics, interleukin-12 (IL-12), interleukin-23 (IL-23), IL-12/23, evidence
    Keywords Medicine (General) ; R5-920 ; Medicine ; R ; DOAJ:Medicine (General) ; DOAJ:Health Sciences ; Therapeutics. Pharmacology ; RM1-950 ; DOAJ:Therapeutics
    Subject code 610
    Language English
    Publishing date 2010-07-01T00:00:00Z
    Publisher Dove Medical Press
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  6. Article ; Online: Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?

    Alwawi, Eihab A / Krulig, Eliana / Gordon, Kenneth B

    Dermatologic therapy

    2009  Volume 22, Issue 5, Page(s) 431–440

    Abstract: Psoriasis is a chronic inflammatory condition that often requires life-long treatment. Conventional therapies have not fully met the needs of psoriatic patients, because of limited efficacy, adverse effects with cumulative use, and patient inconvenience. ...

    Abstract Psoriasis is a chronic inflammatory condition that often requires life-long treatment. Conventional therapies have not fully met the needs of psoriatic patients, because of limited efficacy, adverse effects with cumulative use, and patient inconvenience. In the past decade, biologic immunotherapies have become accepted treatments for psoriasis as a result of perceived efficacy and safety on the part of patients and practitioners. However, most data on these medications come from relatively limited short-term trials. In this review, we will focus on the available long-term data on the efficacy of the biologic agents. We will emphasize the strengths and weakness of the available data of the biologic agents that are Food and Drug Administration (FDA)-approved for the treatment of moderate to severe psoriasis (alefacept, efalizumab,* etanercept, infliximab, and adalimumab), with the inclusion of a newer agent currently under FDA evaluation (ustekinumab).
    MeSH term(s) Biological Products/adverse effects ; Biological Products/therapeutic use ; Biological Therapy/methods ; Dermatologic Agents/adverse effects ; Dermatologic Agents/therapeutic use ; Drug Approval ; Humans ; Psoriasis/drug therapy ; Severity of Illness Index ; United States ; United States Food and Drug Administration
    Chemical Substances Biological Products ; Dermatologic Agents
    Language English
    Publishing date 2009-09
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 1354801-3
    ISSN 1529-8019 ; 1396-0296
    ISSN (online) 1529-8019
    ISSN 1396-0296
    DOI 10.1111/j.1529-8019.2009.01259.x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5181: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Botryomycosis-like pyoderma in the genital region of a human immunodeficiency virus (HIV)-positive man successfully treated with dapsone.

    Rubenstein, Emily / Krulig, Eliana / Cardenas, Vanessa / Kerdel, Francisco A

    International journal of dermatology

    2010  Volume 49, Issue 7, Page(s) 842–843

    MeSH term(s) Anti-Infective Agents/therapeutic use ; Dapsone/therapeutic use ; HIV Infections/complications ; Humans ; Male ; Middle Aged ; Penis/microbiology ; Pseudomonas Infections/drug therapy ; Pyoderma/drug therapy ; Pyoderma/microbiology ; Scrotum/microbiology ; Staphylococcal Skin Infections/drug therapy
    Chemical Substances Anti-Infective Agents ; Dapsone (8W5C518302)
    Language English
    Publishing date 2010-07
    Publishing country England
    Document type Case Reports ; Letter
    ZDB-ID 412254-9
    ISSN 1365-4632 ; 0011-9059 ; 1461-1244
    ISSN (online) 1365-4632
    ISSN 0011-9059 ; 1461-1244
    DOI 10.1111/j.1365-4632.2009.04131.x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui VI Zs.189: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top